Opendata, web and dolomites

ELDICO ED SIGNED

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ELDICO ED project word cloud

Explore the words cloud of the ELDICO ED project. It provides you a very rough idea of what is the project "ELDICO ED" about.

approval    compounds    discovery    hitherto    pharmaceutical    faster    3m    patenting    atomic    incorporating    issue    instruments    conventional    annum    2022    impossible    overcoming    crystallographers    time    84    measured    eldico    particles    pharma    shortening    310m    opening    consuming    mu    entering    forecast    limited    25    drugs    agrochemicals    10    generating    employees    lower    electron    15    sectors    2024    segment    regime    nanomaterials    marketing    size    unlocking    structure    nano    m2    limitations    drug    unmeasurable    18bn    characterisation    500k    commercial    minimum    industry    first    designed    investigations    3d    substances    diffractometer    crystalline    patent    scientific    screened    sub    ed    crystal    market    diffraction    solid    11    ray    pending    exclusively    technique    90    perform    pure    institutes    micro    quality    overcomes    techniques    structural    company    libraries    compound    roi    saving    revenues   

Project "ELDICO ED" data sheet

The following table provides information about the project.

Coordinator
ELDICO SCIENTIFIC AG 

Organization address
address: PARK INNOVAARE DELIVERY LAB
city: VILLIGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELDICO SCIENTIFIC AG CH (VILLIGEN) coordinator 50˙000.00

Map

 Project objective

Crystal structure determination is still a key issue in pharmaceutical industry. Any compound requires its 3D atomic structure to become “fully characterized” for patenting and marketing approval. However, only the structure of the 10% of all crystalline substances can be determine. The reason: Conventional X-ray diffraction methods are limited because they require crystal of a minimum size of 10 x 10 μm2 and high quality to be measured, which are often time consuming or even impossible to produce. For example in drug discovery the 90% of known, but not fully characterized crystalline compounds, could be rapidly screened for their scientific or commercial potential. Although electron diffraction technique overcomes the limitations of current techniques and allows investigations on nano-crystalline systems, currently there are no commercial instruments dedicated exclusively to electron diffraction. With ELDICO ED we bring to the market the first equipment (patent pending) designed to perform electron diffraction. We offer an electron diffractometer for the analysis of solid compounds enabling crystallographers entering the sub-µm regime for structural analysis of hitherto unmeasurable nano-crystalline particles. That way, they produce important structural information faster, with better quality and at lower cost, overcoming the limitations of X-ray analysis. We are opening up a new market segment: Pure Electron Diffraction. Our technology will impact the pharma sector by unlocking the characterisation of the 500k existing potential new drugs in their libraries, shortening time-to-market by 10%, saving €9-18bn per annum for testing and increasing revenues of up to €310M per annum for every new drug that comes to the market. Similar impact in key sectors like research institutes, agrochemicals and Advanced Nanomaterials is expected. With ELDICO ED we forecast generating revenues of €25.3M (ROI: 11.84) and incorporating 15 employees to our company during 2022-2024

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ELDICO ED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ELDICO ED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More  

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More